Objectives: Approximately 50% of gastric cancer patients are locally advanced or metastatic staged at the time of diagnosis. In limited metastatic patients, performing surgery is thought to be related to survival benefit. Thus, we evaluated the effect of the surgery on survival in patients with metastatic gastric carcinoma who have been treated and followed-up in our oncology clinic. Methods: Patients with pathologically verified metastatic gastric cancer between 2009-2016 were included in the study.The patients were divided into 3 groups as those who underwent palliative gastrectomy (group A), who underwent simultaneous gastric surgery and metastasectomy (group B), and who underwent no surgery (group C). Results: One hundred and fifty-three patients, including 35 in the group A, 10 in the group B, and 108 in the group C, were included in the study. There was a significant difference between the groups in terms of the mean age of the patients (60,4, 53 and 63, respectively; p=0.016). Median follow-up time was 8__ampersandsignplusmn;9.6 months. Medianoverall survival (OS) was 20 months in group B, 13 months in group A and 6 months in group C;while OS was found to be significantly increased in surgery groups compared with non-surgery (Group A vs. B, p=0,259; group A vs. C, p__ampersandsignlt;0,001; group B vs. C, p__ampersandsignlt;0,001). Conclusions: It is determined that performing surgery for primary tumor and/or its oligomatastases provided survival benefit in patients with good performance in metastatic gastric cancer. Further prospective studies with higher number of patients are warranted in this subject.